Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Project Information

STROBE

Grant agreement ID: 672768

DOI 10.3030/672768

Project closed

EC signature date 10 April 2015

Start date 1 May 2015

End date 31 October 2015

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

CRITICAL PHARMACEUTICALS LIMITED
United Kingdom